Daniel Fero
InvestorManaging Director at OMX Ventures
Boston, Massachusetts
Writes $500K β $15M checks Β· typically $7.8M
About
Dan Fero is a co-founder and managing partner at OMX Ventures, focusing on platform companies that use a data-driven approach to product discovery and development, and supporting founders turning scientific discoveries into products. He previously was a venture investor at Merieux Equity Partners and a strategy consultant at L.E.K. Consulting in Boston, and co-founded the precision oncology company Uereka Biosciences. He holds a PhD in Biomedical Sciences from UCSD and a BA in biology from Rhode Island College.
ContactΒ· self-published, not guessed
Invests in
BiotechDeep TechHealthtech
Experience
- Nina CapitalInvestment Managercurrent2025 β presentBarcelona
- Nina CapitalInvestment Associate2024 β 2025Barcelona
- BioInnovation Institute (BII)Venture House Advisorcurrent2026 β present
- Novo NordiskSr. Consultant - Open Innovation & Corporate Venturing, Digital Health2023 β 2024Copenhagen, Capital Region, Denmark,
- IESE Business SchoolMBA Candidate2021 β 2023Barcelona, Catalonia, Spain
- AbiChief of Staff - MBA Internship2023Barcelona, Catalonia, Spain
- ZSStrategy Consultant - MBA Internship2022London, England, United Kingdom
- Continuity Care IncExpansion Lead2020 β 2021Austin, TX
- Pattern SciencesFounders Associate2020Austin, Texas, United States
- Eli Lilly and CompanyOperations Lead2019 β 2020Indianapolis, IN
- Eli Lilly and CompanySr. Scientist, Formulation β Technical Services2018 β 2019Indianapolis IN
- Eli Lilly and CompanyScientist, Fill/Finish β Technical Services2016 β 2018Indianapolis, Indiana Area
- MerckOperations Engineering - UVA Summer Internship2015Elkton, Virginia
Skills & more
Time Management3Engineering5Aspen PlusPresentation SkillsChemical EngineeringChemistryTeamwork10Leadership8Communication Skills4Process Support
Languages English Β· Spanish
From Daniel's professional profile.
Investments
Investor
CellsonicsMatterworksMythic TherapeuticsReAx BiotechnologiesType6 Therapeutics
Per the firm's website.
Colleagues at OMX Ventures
Craig Asher
Managing Director at OMX Ventures
Fred Sweeney
Venture Partner at OMX Ventures
John Nawrocki
Chief Financial Officer at OMX Ventures
Natasha Azar
Vice President Investor Relations at OMX Ventures
Nicholas Haft
Managing Director at OMX Ventures
Paul Conley
Chairman & CEO at GENERAL INCEPTION
Swetha Murali
Vice President at OMX Ventures
Tim Richardson
Strategic Advisor at GENERAL INCEPTION
Network3
Craig Asher
Managing Director at OMX Ventures
Nicholas Haft
Managing Director at OMX Ventures
Swetha Murali
Vice President at OMX Ventures
Investors connected to Daniel in public investor directories β a warm-intro map.
Frequently asked questions
- Who is Daniel Fero?
- Dan Fero is a co-founder and managing partner at OMX Ventures, focusing on platform companies that use a data-driven approach to product discovery and development, and supporting founders turning scientific discoveries into products. He previously was a venture investor at Merieux Equity Partners and a strategy consultant at L.E.K. Consulting in Boston, and co-founded the precision oncology company Uereka Biosciences. He holds a PhD in Biomedical Sciences from UCSD and a BA in biology from Rhode Island College.
- Where does Daniel Fero work?
- Daniel Fero is Managing Director at OMX Ventures.
- What does Daniel Fero invest in?
- Daniel Fero invests in Biotech, Deep Tech, Healthtech.
- What check size does Daniel Fero write?
- Daniel Fero typically writes checks of $500K β $15M.
- What companies has Daniel Fero invested in?
- Investments tracked here include Cellsonics, Matterworks, Mythic Therapeutics, ReAx Biotechnologies, Type6 Therapeutics.
- Where did Daniel Fero go to school?
- Daniel Fero studied at IESE Business School (Master of Business Administration - MBA); University of Virginia (Bachelor of Science (BS), Chemical Engineering).
Same school
Also attended IESE Business School269
Avi MeirCo-founder & CEO of PerkJessica WangFP&A Manager at March Capital PartnersCarlos ContiManaging Partner at Inveready Technology Investment GroupIgnacio PuigGeneral Partner at Inveready Technology Investment GroupRobin LiInvestor at GGV CapitalSamuel GilCEO & General Partner at JME Ventures
+ 263 more
Also attended University of Virginia596
Alexis OhanianFounder & General Partner of Seven Seven SixAndy FligelSenior Managing Director at Intel CapitalKandace ElamVice President of GTM Talent at Menlo VenturesTrevor KienzleInvestor at Correlation VenturesFrank RotmanCo-Founder and Partner Emeritus at QED InvestorsMegan LightcapPartner, Creator Fund at Slow Ventures
+ 590 more
Shared employers
Also worked at Nina Capital21
Marc SubiratsGeneral Partner at Nina CapitalMarta G. ZanchiManaging Partner at Nina CapitalSebastian AnastassiouPartner at Nina CapitalYahel HalamishPartner at Nina CapitalFiorela KapllanajAnalyst at Nina CapitalJoan Miquel Marcos SallerasVisiting Analyst at Exceptional Ventures
+ 15 more
Also worked at Novo Nordisk34
Jesper GromadaInvestor at Third Rock VenturesDhiren PatelDigital Pharma Advisor at Excelerate Health VenturesBrian DanielsVenture Partner at 5AM VenturesKasim KutayCEO at Novo HoldingsAviva AminovaGeneral Counsel at Omidyar NetworkTaruho KurodaImpact Partner at Fresco Capital
+ 28 more
Also worked at IESE Business School22
Athary AlmubarakChief Strategy Officer at SVCJavier PedralsPrincipal at Fen VenturesVarun DalalPartner at Inovia CapitalMargarita de la PeΓ±aPrincipal, North America & LatAm at Zacua VenturesMarkus FleischerInvestment Director at 3TS Capital PartnersHenri IsohanniPrincipal at Helen Ventures
+ 16 more
